TherapeuticsMD (NASDAQ:TXMD) Announces Quarterly Earnings Results

TherapeuticsMD (NASDAQ:TXMDGet Rating) announced its quarterly earnings results on Monday. The company reported ($3.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.04) by ($1.09), reports. The business had revenue of $20.92 million during the quarter, compared to the consensus estimate of $30.20 million.

TherapeuticsMD Stock Down 8.2 %

Shares of TXMD opened at $5.93 on Wednesday. TherapeuticsMD has a one year low of $1.99 and a one year high of $31.00. The stock has a fifty day moving average price of $6.31. The company has a market cap of $55.86 million, a P/E ratio of -4.15 and a beta of 1.49.

Analyst Upgrades and Downgrades

Separately, StockNews.com initiated coverage on TherapeuticsMD in a report on Wednesday, October 12th. They issued a “hold” rating for the company.

Insider Buying and Selling at TherapeuticsMD

In other TherapeuticsMD news, major shareholder Rubric Capital Management Lp acquired 7,000 shares of the company’s stock in a transaction dated Friday, October 28th. The shares were acquired at an average cost of $1,000.00 per share, for a total transaction of $7,000,000.00. Following the completion of the purchase, the insider now owns 29,000 shares of the company’s stock, valued at approximately $29,000,000. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 8.80% of the company’s stock.

Institutional Investors Weigh In On TherapeuticsMD

Several hedge funds and other institutional investors have recently modified their holdings of TXMD. Rubric Capital Management LP grew its position in TherapeuticsMD by 46.1% in the 3rd quarter. Rubric Capital Management LP now owns 1,156,953 shares of the company’s stock worth $7,682,000 after purchasing an additional 365,122 shares during the last quarter. Sanders Morris Harris LLC bought a new position in TherapeuticsMD during the third quarter valued at about $268,000. PenderFund Capital Management Ltd. acquired a new position in TherapeuticsMD in the 2nd quarter valued at approximately $313,000. Millennium Management LLC lifted its position in shares of TherapeuticsMD by 339.2% in the 2nd quarter. Millennium Management LLC now owns 57,657 shares of the company’s stock worth $574,000 after acquiring an additional 44,528 shares during the period. Finally, UBS Group AG lifted its position in shares of TherapeuticsMD by 258.1% in the 2nd quarter. UBS Group AG now owns 18,133 shares of the company’s stock worth $180,000 after acquiring an additional 13,069 shares during the period.

About TherapeuticsMD

(Get Rating)

TherapeuticsMD, Inc operates as a women's healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17ß-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system.

Featured Stories

Earnings History for TherapeuticsMD (NASDAQ:TXMD)

Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.